Joo D J, Jung I, Kim M S, Huh K H, Kim H, Choi J S, Choi G H, Kim S I
Department of Surgery, Yonsei University College of Medicine, Seoul, South Korea.
Transplant Proc. 2010 Dec;42(10):4137-40. doi: 10.1016/j.transproceed.2010.09.088.
We compared the results of 2 immunoassay systems (affinity column-mediated immunoassay [ACMIA] and microparticle enzyme immunoassay [MEIA]), regarding hematologic and biochemical values at 2 weeks after liver transplantation.
We obtained 256 blood samples from 35 patients, at 2 weeks after liver transplantation, excluding those from patients who were treated with interacting medications or renal replacement therapy. We also excluded the early mortality cases within 2 weeks of liver transplantation. A Dimension RxL HM with the tacrolimus Flex reagent cartilage was used for the ACMIA and the IMx tacrolimus II for the MEIA method.
The tacrolimus concentrations measured by the ACMIA method correlated closely with those measured by the MEIA method (r = 0.953). However, the weighted concordance correlation coefficient for the repeated-measurement design was 0.74 (95% confidence interval, 0.66-0.85). The discrepancies in the tacrolimus level between the 2 methods was large among samples with low tacrolimus concentrations especially <5 ng/mL. When the difference ratio of the 2 methods ([ACMIA - MEIA]/ACMIA) was analyzed with a linear mixed-effects model to identify significant laboratory findings, there were no significant differences based on hematocrit, renal function, or hepatic function. However, the serum potassium level correlated with the difference ratio of the 2 methods (estimated slope, 10.173; P = .02).
Both the ACMIA and the MEIA methods are precise; however, the ACMIA method has the advantage of fewer pretreatment procedures. In the early liver transplant period, however, there was a difference between the serum tacrolimus concentrations measured by the 2 methods, especially at a low drug concentrations.
我们比较了两种免疫分析系统(亲和柱介导免疫分析[ACMIA]和微粒体酶免疫分析[MEIA])在肝移植术后2周时的血液学和生化指标结果。
我们从35例患者中获取了256份肝移植术后2周的血样,排除了接受相互作用药物治疗或肾脏替代治疗患者的样本。我们还排除了肝移植术后2周内的早期死亡病例。使用配备他克莫司Flex试剂软骨的Dimension RxL HM进行ACMIA检测,使用IMx他克莫司II进行MEIA检测。
ACMIA法测得的他克莫司浓度与MEIA法测得的浓度密切相关(r = 0.953)。然而,重复测量设计的加权一致性相关系数为0.74(95%置信区间,0.66 - 0.85)。在他克莫司浓度较低特别是<5 ng/mL的样本中,两种方法测得的他克莫司水平差异较大。当用线性混合效应模型分析两种方法的差异率([ACMIA - MEIA]/ACMIA)以确定显著的实验室结果时,基于血细胞比容、肾功能或肝功能没有显著差异。然而,血清钾水平与两种方法的差异率相关(估计斜率,10.173;P = 0.02)。
ACMIA和MEIA方法都很精确;然而,ACMIA方法的优势在于预处理程序较少。然而,在肝移植早期,两种方法测得的血清他克莫司浓度存在差异,尤其是在药物浓度较低时。